Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial

Abstract

This is the authors' abstract. We don't add key points for this paper.

Berotralstat was generally well tolerated, provided rapid and sustained reductions in HAE attacks and improved QoL over 96 weeks.

No takes yet. Share an insight, caveat, or question.

Kiani‐Alikhan et al. (2023) studied this question.

View Full Paper

Ask AI

Bookmark

This is the authors' abstract. We don't add key points for this paper.

Berotralstat was generally well tolerated, provided rapid and sustained reductions in HAE attacks and improved QoL over 96 weeks.